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Abstract
Individualized therapies that are tailored to a patient's genetic composition will be of tremendous
value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of
response to epidermal growth factor receptor (EGFR) targeted therapies. In this article, we will
discuss targeted therapies for colorectal cancers (CRC) based on EGFR signaling pathway and
review published data about the potential usefulness of KRAS as a biological marker for response
to these therapies. Results from relevant studies published since 2005 and unpublished results
presented at national meetings were retrieved and summarized. These studies reflected response
(or lack of response) to EGFR-targeted therapies in patients with metastatic CRC as a function of
KRAS status. It has become clear that patients with colorectal cancer whose tumor has an
activating mutation in KRAS do not respond to monoclonal antibody therapies targeting EGFR. It
should now become a standard practice that any patients being considered for EGFR targeted
therapies have their tumors tested for KRAS status and only those with wild-type KRAS being
offered such therapies.
Introduction
Over the past decade, we have witnessed an important
development in the field of cancer treatment: therapy that
is targeted to specific pathways involved in tumor growth
and progression. This mechanistic, target-based approach
is adding to the treatment options for cancer, and these
treatments should be less toxic to normal cells and thus
improve the therapeutic index.
To date, however, the overall effectiveness of targeted ther-
apy in solid tumors has not been as robust as that
achieved, for example, by Gleevec (imatinib) in the treat-
ment of chronic myelogenous leukemia (CML). The dif-
ference in targeted therapy effectiveness in CML compared
with solid tumors can be explained in part by the genetic
etiology of the diseases. CML is caused by a single genetic
alteration that results in a BCR/ABL fusion gene. This gene
produces a chimeric protein with strong tyrosine kinase
activity that can be effectively blocked by Gleevec. For
most solid tumors, on the other hand, although they may
appear to be morphologically similar on microscopic
examination, molecular studies can identify different
genetic alterations in tumors from different patients. Due
to this heterogeneity, an agent targeting one particular
pathway is unlikely to be effective in all patients. Clearly,
there is a need to identify those patients who are most
likely to respond to a specific therapy.
Published: 22 April 2009
Journal of Hematology & Oncology 2009, 2:18 doi:10.1186/1756-8722-2-18
Received: 15 March 2009
Accepted: 22 April 2009
This article is available from: http://www.jhoonline.org/content/2/1/18
© 2009 Chang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
Page 2 of 9
(page number not for citation purposes)
The identification of specific subgroups of patients who
may benefit from a particular targeted therapy has been
most successful in patients with breast cancer. Anti-estro-
gen treatment, an early type of targeted therapy, mainly
benefits patients with estrogen receptor-positive breast
cancer. Trastuzumab, a HER2-targeting monoclonal anti-
body, is most beneficial in patients with tumors that over-
express HER2. Recent data also suggest that genetic
profiling can predict which patients may benefit from
adjuvant therapy after resection of their breast cancers
(e.g., Genomic Health's Oncotype DX® test, which profiles
the expression of 21 genes and makes a prediction about
the likelihood of disease recurrence). These findings show
great promise for identifying patients eligible for treat-
ment with specific targeted therapies, as well as for mak-
ing decisions about dosage and length of treatment.
Individualized therapies that are tailored to a patient's
genetic composition and tests that can predict which ther-
apy he/she will respond to will be of tremendous value for
colorectal carcinoma (CRC). Despite significant progress
in the development of new therapies over the last decade,
CRC remains one of the top three causes of cancer death
in the United States, where it is estimated that 148,810
patients will be newly diagnosed with CRC in 2008, with
49,960 deaths from this disease [1]. Many of these
patients will receive one or more lines of chemotherapy,
but not everyone responds to each regimen. For example,
the targeted agent cetuximab as a single agent has a
response rate of only about 10% in patients with irinote-
can-refractory CRC [2,3]. In other words, the majority of
people receiving cetuximab may not benefit from it, while
incurring all the associated cost and toxicities. Consider-
ing the large number of cases of CRC, this translates into
millions of dollars spent and significant toxicities experi-
enced with no benefit.
In this article, we will discuss targeted therapies for CRC
based on the epidermal growth factor receptor (EGFR) sig-
naling pathway and review published data about the
potential usefulness of the downstream oncogene Kirsten
ras (KRAS) as a biological marker for response to these
therapies. Results from relevant studies published since
2005 and unpublished results presented at national meet-
ings were retrieved and summarized. These studies
reflected response to EGFR-targeted therapies in patients
with metastatic CRC as a function of KRAS status, and
were divided into three groups: (1) previously treated
patients who received cetuximab therapy; (2) previously
treated patients who received panitumumab therapy; and
(3) chemotherapy-naïve patients who received cetuximab
therapy. Data retrieved included KRAS status (wild type
[WT] or mutant type [MT]) and outcome (objective
response rate [RR; complete response + partial response],
time to progression [TTP], and overall survival [OS]).
Descriptive statistics were used to compare outcomes in
the three treatment groups as a function of KRAS status.
Rationale of KRAS Status as a Predictor of Response to 
EGFR Targeted Therapy
The EGFR signaling pathway and targeted therapies for CRC
EGFR is a member of the HER (ErbB) family of human
epidermal growth factor receptors that can promote
tumor cell proliferation in a variety of epithelial malig-
nancies. The EGFR molecules are 170 kd transmembrane
glycoproteins: the extracellular domain has the ligand
binding site and also contains specific sequences that are
involved in dimerization, while the intracellular domain
is a catalytic site that has tyrosine kinase activity. EGFR
binds soluble ligands, including epidermal growth factors
(EGFs) and transforming growth factor-alpha, and the lig-
and/receptor complex then signals the formation of recep-
tor dimers (either homodimers or heterodimers with
other members of the HER family). Dimerization triggers
an intracellular phosphorylation cascade that transmits
the original ligand-generated signal from the cell surface
to the nucleus, causing downstream changes in gene
expression that affect cell proliferation, migration, differ-
entiation, and apoptosis. Overexpression of EGFR has
been detected in many human cancers, including CRC.
Monoclonal antibodies that target EGFR can be effective
as anticancer therapy in several ways. They can block lig-
and binding to the receptor, aborting the process of
dimerization and phosphorylation that allows down-
stream signal transduction. In some cases, the antibody/
receptor complex may also be immunogenic, leading to
antibody-dependent cellular cytotoxicity (ADCC).
Two monoclonal antibodies that target EGFR have clinical
activity against CRC: cetuximab and panitumumab.
Cetuximab is a recombinant, chimeric, IgG1 monoclonal
antibody, while panitumumab is a fully humanized IgG2
antibody. Because of their differing isotypes, it is possible
that these two antibodies may differ in their mechanism
of action, but this has not been documented. Cetuximab
has been demonstrated to improve response rate, time to
progression, and overall survival when added to irinote-
can for patients with irinotecan-refractory metastatic CRC
[2]. Both cetuximab and panitumumab have been shown
to improve outcomes in patients with chemo-refractory
metastatic CRC compared with best supportive care [4,5].
KRAS is an important molecule in the EGFR signaling pathway
KRAS encodes a membrane-associated GTPase that is an
early player in many signal transduction pathways. KRAS
acts as a molecular on/off switch for the recruitment and
activation of proteins necessary for the propagation of
growth factor and other receptor signals, such as c-Raf and
PI 3-kinase. When activated, KRAS is involved in theJournal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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dephosphorylation of GTP to GDP, after which it is
turned off. The rate of GTP to GDP conversion can be sped
up dramatically by an accessory protein of the Guanine
nucleotide activating protein (GAP) class, for example
RasGAP. KRAS can also facilitate the release of bound
nucleotide by binding to proteins of the Guanine Nucle-
otide Exchange Factor (GEF) class, for example Soverall
survival-1. HRAS is subsequently released from the GEF
and quickly re-binds to the now available GTP resulting in
HRAS activation.
When EGF ligand binds to the extracellular part of the
EGFR receptor, the receptor dimerizes and its enzymatic
activity is activated, resulting in phosphorylation of the
intracellular domain. Subsequently, cellular effectors bind
to phosphorylated residues of the intracellular domain
and are activated, mainly through relocalization to the
plasma membrane. When an activating mutation occurs
in the KRAS gene, the RAS G-protein activates the
mitogen-activated protein kinase (MAPK) signaling cas-
cade downstream of EGFR. This may bypass the need for
ligand binding to EGFR, conferring resistance to therapies
like cetuximab or panitumumab which target the EGFR
extracellularly.
Activating mutations of the KRAS gene have been widely
studied as markers for cancer prognosis. These gene muta-
tions, principally in codons 12 and 13, occur in up to one-
half of CRCs, and population-based studies have sug-
gested that the mutations might be associated with some
tumor phenotypes [6].
KRAS mutation predicts unresponsiveness to EGFR-
targeted monoclonal antibody therapy in previously 
treated patients with metastatic CRC
The Data for Cetuximab
Table 1 summarizes the results of 12 studies in which pre-
viously treated patients with metastatic CRC received
treatment with cetuximab alone or cetuximab as part of a
multi-drug regimen (in combination with either irinote-
can or oxaliplatin) [7-18].
Across all studies, approximately one-third of patients
(median 36%, range 24% – 44%) had KRAS MT tumors.
In the 10 studies that reported objective tumor response
to cetuximab-containing therapy, the median RR in
patients with KRAS WT tumors was 35% (range 12% –
42%) compared with 0% (range 0% – 6%) in patients
with KRAS MT tumors. TTP was reported in 6 studies, with
a median TTP of 6.1 months (range 1.8 months – 7.9
months) in patients with KRAS WT tumors compared
with 3.0 months (range 1.8 months – 3.7 months) in
patients with KRAS MT tumors. OS was reported in 6 stud-
ies, with median values of 11.5 months (range 9.5
months – 16.3 months) compared with 6.9 months
(range 4.2 months – 10.1 months) associated with KRAS
WT and KRAS MT, respectively.
In summary, all studies discussed above using cetuximab
either as a monotherapy or in combination with either iri-
notecan- or oxaliplatin-based chemotherapy for previ-
ously treated metastatic CRC patients showed that KRAS
mutational status clearly predicts unresponsiveness to
cetuximab.
The study reported by Di Fiore and colleagues [11] under-
scores the importance of using sensitive molecular meth-
ods to ensure efficient mutation detection. In this study,
59 patients with previously treated metastatic CRC were
treated with cetuximab plus either irinotecan- or oxalipla-
tin-based chemotherapies. Using direct sequencing of
DNA extracted from tumor samples, the investigators
detected a KRAS mutation in 16 out of 59 (27%) patients.
Of these 16 patients, 13 had a progression of disease and
three had stable disease. No KRAS mutation was found in
the 12 patients with a complete or partial tumor response.
The investigators then screened the tumors without
detectable KRAS mutations, using two sensitive methods
able to specifically detect KRAS exon 2 mutations: a mul-
tiplex SNaPshot assay based on primer extension able to
detect the different KRAS mutations simultaneously in a
single tube, and a fluorescent PCR-LCR assay. These two
analyses were performed on samples from 11 out of 12
patients with either complete response or partial
response, in 15 out of 16 patients with stable disease, and
in 15 patients with disease progression, all of whom had
no mutations revealed by direct sequencing of tumor
DNA. Five additional KRAS mutations were detected by
both methods and one mutation was detected only by
PCR-LCR assay. These six additional mutations were
found in two patients with stable disease and four patients
with disease progression. SNaPshot and PCR-LCR assays
confirmed the absence of KRAS mutations in the CR/PR
patients. Therefore, in this series of 59 patients with met-
astatic CRC, sequencing analysis supplemented by SNaP-
shot multiplex and PCR-LCR assays led to the detection of
a KRAS mutation in 22 samples (37%), rather than the 11
samples (27%) with direct sequencing alone.
Several studies have suggested that the predictive value of
KRAS in determining response to cetuximab-containing
regimens may be improved by combining it with other
predictive factors. [15] determined the KRAS mutation
status and mRNA expression levels of the EGFR ligands
amphiregulin and epiregulin in 95 patients with primary
CRC treated with cetuximab and irinotecan and correlated
these variables with response and overall survival. They
found that amphiregulin and epiregulin expression influ-
enced RR and OS in patients with KRAS WT tumors, but
not in patients with KRAS MT tumors, and concluded thatJournal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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Table 1: KRAS and treatment response to Cetuximab or Panitumumab in previously treatment patients with colorectal cancer.
Study Treatments KRAS N (%) RR, N (%) TTP (months) OS (months) Remarks
Cetuximab Studies
Moroni, 2005 CTX = 12 WT 16 6 (38%) NA NA KRAS MT has worse RR.
CTX + IRI = 9 MT 5 (24%) 0 (0%) NA NA
Lievre, 2006a CTX = 1 WT 17 11 (36.7%) NA 16.3 KRAS MT has worse RR 
and OS.
CTX + IRI = 25 MT 13 (43.3%) 0 NA 6.9
CTX + FOLFIRI = 4
Benvenuti, 2007 CTX = 12 WT 32 10 (31.3%) NAb NA KRAS MT has worse RR 
and TTP.b
CTX + IRI = 11 MT 16 (33.3%) 1 (6.3%) NAb NA
Finocchiaro, 2007 CTX = 5 WT 49 13 (26.5%) 6.1 10.8 KRAS MT has worse RR, 
TTP, and OS.
CTX + IRI = 77 MT 32 (39.5%) 2 (6.3%) 3.7 8.3
CTX + OX = 3
Di Fiore, 2007 CTX + IRI/OX WT 37 12 (32.4%) 5.5 NA KRAS MT has worse RR 
and TTP.
MT 22 (37.3%) 0 3.o NA
Khambata-Ford, 2007 CTX WT 50 6 (12%) 2.0 NA KRAS MT has worse RR.
MT 30 (37.5%) 0 2.0 NA
Lievre, 2008a CTX = 2 WT 65 26 (40.0%) 7.9 14.3 KRAS MT has worse RR, 
TTP, and OS.
CTX + IRI = 78 MT 24 (27.0%) 0 2.5 10.1
CTX + FOLFIRI = 9
DeRoock, 2008 CTX = 30 WT 67 27 (40.9%) 6.0 10.8 KRAS MT has worse RR, 
TTP, and OS.
CTX + IRI = 83 MT 46 (40.7%) 0 3.0 6.8
Tejpar, et al. 2008 CTX + IRI WT 62 NA NA 11.5 KRAS WT has worse OS.
MT 33 (35%) NA NA 4.2
Stoehlmacher, 2008 CTX + IRI/OX WT 22 NA NA NA KRAS WT did not respond.
MT 8 (26%) 0 NA NA
Tejpar, et al. 2008a IRI + CTX standard 
dose
WT 23 7 (30.4%) NA NA KRAS MT has worse RR.
MT 20 (44.4%) 0 NA NA
IRI + CTX escalated 
dose
WT 31 13 (41.9%) NA NA Escalated dose did not 
overcome KRAS MT.
MT 12 (27.3%) 0 NA NA
Karapetis, et al. 2008 CTX WT 117 15 (12.8%) 3.7 9.5 CTX also improved quality 
of life in KRAS WT patients.
MT 81 (40.9%) 1 (1.2%) 1.8 4.5
BSC WT 113 NA 1.9 4.8
MT 83 (42.3%) NA 1.8 4.6
Panitumumab 
Studies
Moroni, 2005 PAN WT 5 2 (40%) NA NA KRAS MT did not have 
impact on response.
MT 5 (50%) 2 (40%) NA NA
Benvenuti, 2007 PAN WT 15 3 (20%) NAb NA KRAS MT has worse RR 
and TTP.b
MT 10 1 (10%) NAb NA
Amado, 2008 PAN WT 124 21 (16.9%) 3.1 8.1 KRAS MT has worse RR, 
TTP, and OS.
MT 84 (40.4%) 0 1.9 4.9
BSC WT 119 0 1.8 7.6
MT 100 (45.7%) 0 1.8 4.4
Freeman, 2008 PAN WT 38 4 (10.5%) 4.1 10.7 KRAS MT has worse RR, 
TTP, and OS.
MT 24 (38.7%) 0 1.9 5.6
a The 2006 and 2008 studies by Lievre and coworkers were based on independent patient series.
b For all patients (CTX and PAN), average TTP was 3.7 months for patients with wild type KRAS versus 1.7 months for patients with mutant KRAS.
Abbreviations: CTX = cetuximab; PAN = panitumumab; IRI = irinotecan; Ox = oxaliplatin; Cap = capcitabine; BSC = best supportive care; WT = wild type; 
MT = mutant-type; RR = objective response rate (complete response + partial response); TTP = time to progression, OS = overall survival; NA = Not 
Available or Not Applicable.Journal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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the combined use of these markers may allow improved
prediction of outcome to cetuximab plus irinotecan.
Khamabata-Ford and colleagues [12] attempted to sys-
temically identify markers that are associated with disease
control in patients treated with cetuximab as a mono-
therapy. The trial enrolled 110 patients with metastatic
CRC who had received at least one prior therapy. Tran-
scriptional profiling was conducted on RNA from manda-
tory pretreatment metastatic biopsies to identify genes
whose expression correlated with best clinical responses.
Consistent with the findings of Tejpar et al., they found
that patients with KRAS WT tumors and patients with
tumors that express high levels of epiregulin and
amphiregulin are more likely to have disease control and
increased TTP with cetuximab.
Stoehlmacher and colleagues [16] evaluated the predic-
tive value of KRAS mutations and polymorphisms of
EGFR and IgG-Fc-receptor in 40 patients with metastatic
CRC receiving cetuximab-containing chemotherapy (in
combination with irinotecan, FOLFIRI, or FOLFOX). They
found that both KRAS and the EGF-A16G polymorphism
significantly predicted response to cetuximab-containing
treatment combinations, regardless of the specific regi-
men selected.
The Data for Panitumumab
The outcomes in 4 studies in which previously treated
patients with metastatic CRC received treatment with pan-
itumumab as monotherapy are similar to those reported
above for cetuximab (Table 1). In the two largest studies
[19,20], no patients with KRAS MT tumors showed an
objective tumor response to panitumumab. In each case,
KRAS MT was also associated with reduced TTP and OS.
The data reported by Benvenuti and colleagues [9]
showed a two-fold increase in RR associated with KRAS
WT status compared with KRAS MT status (20% vs. 10%,
respectively). KRAS MT status did not show an impact on
tumor response in the report from Moroni and colleagues
[7], but the patient numbers in this study were very low,
with only 5 patients each showing KRAS WT and KRAS MT
status.
In the report from Amado and colleagues [19], patient
outcomes with panitumumab treatment were compared
with outcomes in a matched population of patients who
received best supportive care only. It is interesting to note
here that KRAS status did not have an effect on TTP in the
absence of treatment with the EGFR-targeting therapy,
although KRAS MT appeared to be associated with
reduced OS in both treatment groups.
Most recently, interim results from the PRECEPT study
were reported at the 2008 ASCO annual meeting (data
from final analysis not available for inclusion in Table 1)
[21]. This phase II, open-label, single-arm trial was
designed to prospectively estimate the efficacy of panitu-
mumab plus FOLFIRI treatment as a function of tumor
KRAS status in patients undergoing second-line treatment
for metastatic CRC. A total of 110 patients with metastatic
CRC with progression after first-line oxaliplatin-based
chemotherapy plus bevacizumab were enrolled in this
study. Patients received panitumumab and FOLFIRI every
2 weeks until disease progression or intolerability. Effi-
cacy endpoints included objective response rate, progres-
sion-free survival, and overall survival by KRAS status.
Data reported from the interim analysis supported previ-
ous studies showing that patients with KRAS MT tumors
do not respond to panitumumab therapy.
In summary, as with cetuximab, all available studies (with
the exception of the very small data set reported by
Moroni et al. [7] with panitumumab as monotherapy or
in combination with other agents for previously treated
metastatic CRC patients show that KRAS mutation status
clearly predicts response to panitumumab.
KRAS mutation predicts unresponsiveness to EGFR-
targeted monoclonal antibody therapy in first line 
treatments for metastatic CRC
The aforementioned studies demonstrated the predictive
value of KRAS for outcomes of EGFR-targeted monoclonal
antibody therapy in patients with metastatic CRC who
had received previous chemotherapy. Does the predictive
value of KRAS also apply to chemotherapy-naïve patients?
At the 2008 ASCO annual meeting, at least four studies
confirmed that it does. (Table 2) [22-25] Three of these
studies, presenting results from the phase III CRYSTAL
and CAIRO2 trials and the phase II OPUS trial, compared
outcomes in patients treated with standard chemotherapy
regimens (FOLFIRI, CapOxBev, FOLFOX) with or without
the addition of cetuximab [22,24,25]. The fourth study
compared an every-2-week schedule of cetuximab with
the approved weekly regimen [23].
Across all of the treatment arms shown in the 4 studies in
Table 2, a median of 40% of patients (range 33% – 46%)
had KRAS MT tumors. For patients with KRAS WT tumors
compared with KRAS MT tumors, the median RRs to
cetuximab-containing treatment regimens (4 study arms
reporting) were 58% (range 28% – 61%) and 33% (range
0% – 36%), respectively, and the median TTP values (4
study arms reporting) were 9.7 months (range 7.7 months
– 10.5 months) and 6.6 months (range 5.5 months – 8.6
months), respectively. OS was reported in only one study
[24], which noted a small increase in OS associated with
KRAS WT compared with KRAS MT (22.2 months versus
19.1 months, respectively).
In summary, under controlled conditions in these studies
of first-line treatment in metastatic CRC, KRAS mutationJournal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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was found to be a predictive marker for lack of response
to cetuximab treatment, either alone or in combination
with irinotecan- or oxaliplatin-based chemotherapies.
It should be noted that, at least in the first line setting,
there is a concern that cetuximab may actually have detri-
mental effects for patients with KRAS MT tumors. In the
three studies designed to compare outcomes from stand-
ard treatment with or without cetuximab [22,24,25],
patients with KRAS MT tumors showed a decrease in TTP
in the cetuximab-containing arm compared with the
standard treatment arm, although the difference in each
individual study did not reach statistical significance. In
the CARO2 study which compared CapOxBev with and
without cetuximab, patients whose tumor has MT type
KRAS did worse which did reach statistical significance
[24]. Thus, not only does cetuximab appear to have no
benefit in patients with KRAS MT tumors, it may have a
negative effect on outcome, particularly in combination
with bevacizumab and chemotherapy in first line treat-
ment of metastatic colorectal cancer.
KRAS and skin rash are independent predictive markers for 
response to EGFR-targeted monoclonal antibody 
therapies
Long before KRAS emerged as a predictive marker for
responsiveness to EGFR monoclonal antibody targeted
therapy, it was well known that skin rash was a very good
surrogate marker for responsiveness to EGFR targeted
therapies. An obvious question is whether skin rash and
KRAS are independent predictors. The recent analysis of
the KRAS data from the EVEREST study shed some light
on this question [17]. In this study, patients with grade 0/
1 skin reactions after 22 days of treatment with irinotecan
and standard-dose cetuximab were randomized to receive
a standard dose (250 mg/m2) (Arm A) or escalated doses
(up to 500 mg/m2) (Arm B) of cetuximab. The results
demonstrated that, in patients with metastatic CRC after
failure of irinotecan-based therapy, treatment efficacy
could be improved by escalating the dose of cetuximab in
combination with standard-regimen irinotecan compared
with standard-dose cetuximab for patients with grade 0/1
skin reactions. To determine whether dose escalation was
also able to induce response in patients with mutated
Table 2: KRAS and treatment response to Cetuximab-containing regiments in chemotherapy-naïve patients with colorectal 
carcinoma.





Bokemeyer, 2008 FOLFOX + CTX WT 61 37 (60.7%) 7.7 NA KRAS MT has worse RR and TTP.
Cetuximab may have detrimental effects in 
KRAS MT.
MT 52 (46.0%) 17 (32.7%) 5.5 NA
FOLFOX WT 73 27 (37.0%) 7.2 NA
MT 47 (39.2%) 23 (48.9%) 8.6 NA
Cervantes, 2008 CTX WT 29 8 (27.6%) NA NA Patients were treated with CTX first, then 
in combination with chemo.
KRAS MT has worse RR and TTP.
MT 19 (39.6%) 0 NA NA
CTX + FOLFIRI WT 29 16 (55.2%) 9.4 NA
MT 19 (39.6%) 6 (31.6%) 5.6 NA
Punt, 2008 CapOxBev+CTX WT 153 NA 10.5 22.2 KRAS MT has worse TTP, and OS.
Cetuximab may have detrimental effects in 
KRAS MT.
MT 93 (37.8%) NA 8.6 19.1
CapOxBev WT 152 NA 10.7 23.0
MT 103 (40.4%) NA 12.5 24.9
Van Custem, 2008 FOLFIRI + CTX WT 172 102 (59.3%) 9.9 NA KRAS MT has worse RR and TTP.
Cetuximab may have detrimental effects in 
KRAS MT.
MT 105 (37.9%) 38 (36.2%) 7.6 NA
FOLFIRI WT 176 76 (43.2%) 8.7 NA
MT 87 (33.1%) 35 (40.2%) 8.1 NA
Abbreviations: CTX = cetuximab; PAN = panitumumab; IRI = irinotecan; Ox = oxaliplatin; Cap = capcitabine; Bev = bevacizumab; BSC = best 
supportive care; WT = wild type; MT = mutant type; NA = Not Available or Not Applicable; RR = objective response rate (complete response + 
partial response); TTP = time to progression; OS = overall survival.Journal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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KRAS, the authors analyzed KRAS mutation status using
archived tissue from 77 of 89 randomized patients. For
patients on Arm A, who received the standard dose of
cetuximab, response rates were 21.1% and 0% for wild-
type KRAS and mutant KRAS, respectively. For patients on
Arm B, who received escalated doses of cetuximab, the
response rates for patients with wild-type KRAS and
mutant KRAS were 46.4% and 0%, respectively. Therefore,
improved response was mainly seen in the patients with
wild-type KRAS tumors, while increased dose of cetuxi-
mab did not overcome reduced response in mutant KRAS
tumors.
Although patients originally selected for randomization
had a 0/1 skin reaction after 22 days of standard treat-
ment, with continued treatment some patients developed
a more severe cutaneous response to the medication. Skin
reaction predicted clinical outcomes in patients with both
KRAS WT and KRAS MT tumors, with a grade 2/3 reaction
associated with improved progression-free survival (PFS)
compared with a grade 1/2 reaction in each group. How-
ever, the overall range of PFS values was significantly
higher in the KRAS WT group; at 200 days, the average PFS
associated with a Grade 2/3 reaction was 60% in the wild-
type KRAS group compared with approximately 34% in
the mutant KRAS group. The ability of skin reaction to dis-
tinguish subgroups of KRAS WT or MT patients with dif-
fering outcomes argues that skin reaction and KRAS status
are independent predictors of response to cetuximab-
based treatment.
Summary
Recent developments in individualized therapies for CRC
are having a significant impact on current clinical practice
and on the future development of treatments for this dis-
ease. To date, clinical activity has been assessed in over
2500 patients treated with cetuximab/panitumumab,
either as a single agent or in combination with both
FOFIRI and FOLOX chemotherapy, in both chemother-
apy-refractory and chemotherapy-naïve settings. There is
strong evidence that mutated KRAS in tumors predicts
unresponsiveness to EGFR-targeted antibody therapies.
Furthermore, data from the CRYSTAL, OPUS, and
CAIRO2 studies showed evidence that the addition of
cetuximab to chemotherapy (both oxaliplatin- and iri-
notecan-based) may have detrimental effects on patients
with KRAS MT tumors. It is therefore important to test
KRAS status in tumors of all patients being considered for
EGFR-targeted antibody therapies, and only those
patients with KRAS WT tumors should receive such treat-
ments. Randomized prospective trials are not needed nor
are they ethical to prove this concept further. In fact, the
European Medicines Agency (EMEA) approved panitumu-
mab only for patients with KRAS wild-type tumors. It is
likely that verification of KRAS wild-type status will be
required by the United States Food and Drug Administra-
tive (US FDA) for cetuximab and panitumumab treatment
in the near future.
Several commercial DNA sequencing-based KRAS tests for
tumor tissues are available. Developing and validating
more sensitive, reproducible, and affordable KRAS tests
that can be used in the clinic is an important task that
industry and government should undertake in order to
maximize the value of this biomarker for individualized
therapies in CRC.
Future directions
Moving forward, there are several issues, both immediate
and long term, that need to be addressed:
Modification of current and future trial designs
At least two large randomized phase III trials in the U.S.
need to be modified. The CALGB/SWOG 80405 study
compares bevacizumab and cetuximab either alone or
together in combination with FOLFIRI or FOLFOX chem-
otherapy in patients with untreated metastatic CRC. This
study, initially designed to enroll 2289 patients, has
already accrued about 1400 patients. While the modifica-
tion plan is still being formulated, it is almost certain that
KRAS testing will be required and only patients with wild-
type KRAS would be allowed for randomization. A second
study, the iBET trial, which was developed based on the
BRiTE data, tests whether continuing bevacizumab
beyond progression on first line therapy would be benefi-
cial. However, as second line therapy, while patients are
randomized to study arms with or without bevacizumab,
all patients receive cetuximab. This was probably a for-
ward-thinking design when it was conceived, because the
EPIC study showed activity of cetuximab in second line
therapy for irinotecan-naïve patients. With more convinc-
ing KRAS data, it undoubtedly requires modification. One
option would be to completely drop the cetuximab com-
ponent and to only test the question of whether continu-
ation of bevacizumab beyond progression on first line
therapy is beneficial. However, if cetuximab is to be con-
tinued as a component in this trial, KRAS testing should
be required.
In addition, given the clear predictive value of KRAS sta-
tus, all future trials involving EGFR-targeted monoclonal
antibodies should incorporate KRAS testing.
KRAS data may or may not predict response to small 
molecule enzyme inhibitors
The EGFR monoclonal antibodies target the extracellular
domain of the receptor. Therefore, tumors with KRAS
mutations that confer constitutive activation of intracellu-
lar downstream pathways may not respond to these mon-
oclonal antibody-targeted therapies. This may not applyJournal of Hematology & Oncology 2009, 2:18 http://www.jhoonline.org/content/2/1/18
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to small molecule inhibitors that specifically target the
intracellular downstream protein kinases. At present,
small molecule inhibitors have not shown significant
benefit in CRCs. However, when more potent agents of
this type are developed, they will need to be determined
whether their efficacy is influenced by the presence of
KRAS mutations in the tumor.
Therapies for KRAS mutant tumors
The emerging KRAS data leaves open the question of what
to do for patients with KRAS mutant tumors. As EGFR
monoclonal antibody-targeted therapies are being taken
away, these patients are left with only two lines of therapy,
either FOLFOX or FOLIRI along with bevacizumab. There
is a pressing need to develop novel therapies for this
group of patients. Future trials with novel biologically
rational agents should be developed for these patients.
The need for other predictive biomarkers
While data clearly indicate that KRAS MT predicts unre-
sponsiveness to EGFR-targeted monoclonal antibody
therapies, KRAS WT does not necessarily predict response:
the median response rate of wild-type KRAS tumors in the
studies reviewed here was only 35%. Obviously, other
markers or combinations of markers that better predict
response to a chosen treatment are urgently needed. Mark-
ers currently under study include EGFR copy number,
EGFR ligands, microsatellite instability (MSI), PTEN,
PI3K, and others. However more data will be needed to
incorporate these and other novel markers into clinical
practice.
The use of genetic signatures to select treatments
In breast cancer, data have shown that genetic profiling
may predict which patients benefit from adjuvant therapy
after resection of their breast cancers. It is quite possible
that certain genetic signatures will predict response (or
lack of response) to certain regimens for CRC. The studies
in this field are being actively pursued.
Conclusion
We have made significant progress in the management of
CRC, and to some degree, we have been successful in con-
verting metastatic CRC to a chronic disease state. Targeted
therapy, which has been the hot topic for the past decade,
now plays a key role in the treatment of CRCs. How to use
available agents to maximize the benefit and minimize
the associated cost and toxicity is a critical question.
Undoubtedly, the future of oncology lies in individual-
ized treatment based on each person's genetic composi-
tion. To this end, we have taken a huge step forward with
KRAS, and within the next decade, it is likely that we will
see more and more biomarkers come into clinical practice
to direct individualized treatment.
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